Bio

Mr. Cali is a Managing Partner at Noble Capital Markets, Inc. Nathan Cali has more than 19 years of combined healthcare, biotechnology, and pharmaceutical experience. He has led the Healthcare Investment Banking franchise at Noble since 2017 and, was previously a sell-side analyst for 9 years with expertise and publications cover many areas of biotechnology, specialty pharmaceuticals (branded and generics), and medical devices. Mr. Cali is a Board Member of Precise Bio, a tissue engineering, biomaterials, cell technologies, including, cardiology, orthopedics, and dermatology. He was previously a Board observer of Eledon Pharmaceuticals (ELDN:NASDAQ, f.k.n.a. Anelixis Therapeutics, Inc.), a phase II biotechnology company pursuing transplant, autoimmune, and neurology treatments. He is currently a Committee Member at the Moffitt Cancer Center for Commercialization. Mr. Cali has been quoted in most business journals including Reuters, BioMed Reports and the Washington Business Journal for his work as a sells-side analyst. Mr. Cali started his career in healthcare at Andrx Corporation, a biotechnology and specialty pharmaceuticals company known for its expertise in the development of controlled-release drugs. Mr. Cali was a corporate manager dealing in finance, state taxation, corporate governance, patents, drug distribution and business development for the biotechnology firm. Andrx was purchased by Watson Pharmaceuticals in 2006 for $2.0 billion in cash. Prior to joining NOBLE, Mr. Cali gained investment experience as a portfolio account analyst/manager at Franklin Templeton Investments. Mr. Cali holds a B.S. in Finance from The Florida State University and an M.B.A. in Finance from Nova Southeastern University. Nathan also currently holds series 7, 79, 86, and 87 FINRA designations.